BioLine Rx licenses kidney drug

The treatment was invented by Professor Ariella Oppenheim of the Department of Hematology and Dr. Yosef Haviv of the Department of nephrology at Jerusalem's Hadassah University Hospital.

By JERUSALEM POST BUSINESS STAFF
August 28, 2007 07:58

BioLine Rx Ltd. announced Monday that it signed a worldwide, exclusive license agreement with Gene Vector Technologies Ltd. to develop and commercialize BL-4040, for the treatment of acute kidney injury. Financial terms were not disclosed. The treatment was invented by Professor Ariella Oppenheim of the Department of Hematology and Dr. Yosef Haviv of the Department of nephrology at Jerusalem's Hadassah University Hospital.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Cookie Settings